ArticleJournal of managed care & specialty pharmacy2016

Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.

Lisa Bloudek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.